TGFB1 and triple-negative breast carcinoma: Recent preclinical studies have demonstrated synergistic efficacy of novel combinations, including simultaneous anti-TGF-β/VEGF bispecific antibody with PD-1 blockade [47] and anti-TGF-β/PD-L1 bispecific antibody promoting T cell infiltration in triple-negative breast cancer [48].